In subgroup analysis of lung cancer and ILD patients, no significant difference in the risk of bleeding discontinuation was found between the R group and the E groups, suggesting that different underlying pulmonary diseases have different impact on bleeding with each FXa inhibitor. The gene discussed is F10; the disease is lung carcinoma.